Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

SomnoMed Limited Receives U.S. Approval For Sleep Apnea Devices

SomnoMed Limited (ASX:SOM) has received FDA 510(k) approval from the U.S. Department of Health & Human Services for its sleep apnea devices, allowing it to start sales in July.

The approvals were received for its new SomnoDent® Fusion Classic and SomnoDent® Fusion Flex oral appliances that were introduced at conventions at the beginning of June.

These have exchangeable wings, which makes adjustments of the forward position of the SomnoDent® device easier for the practitioner and patient.

Both products offer improvements over existing sleep apnea devices and a greater level of patient comfort.

The company's products are already distributed throughout 16 countries in Europe, which represents 40% of its global sales.

Outlook for European sales volume and revenue growth in FY14/15 is strong.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX "Small and Mid-cap" stocks with distribution in Australia, UK, North America and Hong Kong / China.